Revance Therapeutics (FRA:RTI) FCF Margin % : -136.92% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Revance Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Revance Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was €-65.4 Mil. Revance Therapeutics's Revenue for the three months ended in Mar. 2024 was €47.8 Mil. Therefore, Revance Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -136.92%.

As of today, Revance Therapeutics's current FCF Yield % is -74.12%.

The historical rank and industry rank for Revance Therapeutics's FCF Margin % or its related term are showing as below:

FRA:RTI' s FCF Margin % Range Over the Past 10 Years
Min: -37391.98 Med: -13721.84 Max: -94.78
Current: -94.78

During the past 13 years, the highest FCF Margin % of Revance Therapeutics was -94.78%. The lowest was -37391.98%. And the median was -13721.84%.

FRA:RTI's FCF Margin % is ranked better than
55.07% of 1046 companies
in the Biotechnology industry
Industry Median: -141.025 vs FRA:RTI: -94.78

Revance Therapeutics FCF Margin % Historical Data

The historical data trend for Revance Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revance Therapeutics FCF Margin % Chart

Revance Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-26,465.59

-1,192.31

-298.10

-148.42

-95.48

Revance Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-153.73	-91.37	-97.69	-63.77	-136.92

Competitive Comparison of Revance Therapeutics's FCF Margin %

For the Biotechnology subindustry, Revance Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revance Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revance Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Revance Therapeutics's FCF Margin % falls into.

Revance Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Revance Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-204.913	/	214.615
	=	-95.48 %

Revance Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-65.424	/	47.781
	=	-136.92 %

Revance Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Revance Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Revance Therapeutics (FRA:RTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revance Therapeutics Inc (FRA:RTI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RVNC:USA RTI:Germany

Address

1222 Demonbreun Street, Suite 2000, Nashville, TN, USA, 37203

Website

https://www.revance.com

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

Revance Therapeutics (FRA:RTI) Headlines

No Headlines